EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)

Contributed by: ACCESSWIRE

Logo

Tags

Healthcare & Pharmaceutical

Moderna, Inc.

NASDAQ:MRNA

Company Update

More Like This

Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)

Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union

Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

New RSV vaccine could prevent 5,000 infant hospitalisations

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

National RSV vaccination programme announced